Cannabis Health/LinkedIn
Mar 9, 2026, 10:16
Ananda Pharma Cleared to Launch Phase 2 Trial for Endometriosis Pain Treatment – Cannabis Health
Cannabis Health shared a post on LinkedIn:
“Ananda Pharma Ltd has cleared the final regulatory hurdle needed to begin its ENDOCAN Phase 2 clinical trial in women with endometriosis-associated pain.
The company has received approval from the MHRA and NHS Health Research Authority to commence dosing of its proprietary MRX1 CBD oral solution.
Melissa Sturgess, CEO of Ananda Pharma, said: ‘The reason this study is different is that we are using a product that could go all the way through to regulatory approval and be able to be prescribed by a doctor on the NHS.’ ”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 29, 2026, 01:10Are Normal-BMI Women with PCOS at Higher Risk of Adverse Obstetric and Perinatal Outcomes After FET? – RBMO
-
Apr 28, 2026, 16:13Christina Neophytou: Exceptional Learning and Conversation at the EEL Conference
-
Apr 28, 2026, 16:07Sandro Esteves: Male Infertility Work-Up, Are We Doing Enough or Too Little?
-
Apr 28, 2026, 16:04Angelos Daniilidis: Amazing Experience at the 8th European Endometriosis League Congress
-
Apr 28, 2026, 15:57Marco Zaccaria: Patient-Centred Infertility Care Takes Centre Stage at HARTUS2026
-
Apr 28, 2026, 15:46Understanding the Risks of Dilation and Curettage – Fertility Plus
-
Apr 28, 2026, 15:44Does Coffee Drinking Affect IVF Sucess? – Fertility Plus
-
Apr 28, 2026, 15:41Apply to Be an ESHRE 5 Young Ambassador – ESHRE
-
Apr 28, 2026, 15:35Szabó Gábor: Best Poster Award at the EEL Congress